Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease  by Andersen, Charlotte U. et al.
Respiratory Medicine (2012) 106, 1749e1755Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedDiagnostic and prognostic role of biomarkers for
pulmonary hypertension in interstitial lung diseaseCharlotte U. Andersen a,*, Søren Mellemkjær b, Jens Erik Nielsen-Kudsk b,
Elisabeth Bendstrup c, Ulf Simonsen a, Ole Hilberg caDepartment of Biomedicine, Aarhus University, Wilhelm Meyers Alle 4, Dk-8000 Aarhus, Denmark
bDepartment of Cardiology, Aarhus University Hospital, Denmark
cDepartment of Respiratory diseases and Allergology, Aarhus University Hospital, Denmark
Received 30 April 2012; accepted 11 September 2012
Available online 30 September 2012KEYWORDS
Biomarkers;
Lung fibrosis;
NT-proBNP;
Troponin-T;
fibrin D-dimer* Corresponding author. Tel.: þ45 87
E-mail address: cua@farm.au.dk (C
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.201Summary
Background: Pulmonary hypertension (PH) is an important complication to interstitial lung
disease (ILD). The aim of the present study was to investigate the relation of NT-proBNP, fibrin
D-dimer, troponin-T, uric acid and exhaled nitric oxide (NO) to the presence of PH and
mortality in ILD.
Methods: In a previously described cohort of 212 ILD patients of whom 29 had PH, levels of the
above mentioned biomarkers were analyzed as routine tests.
Results: A value of NT-proBNP below 95 ng/l had a negative predictive value for PH of 99% (95%
CI: 94e100). Values of troponin-T were higher in patients with PH (median (inter quartile
range) Z 9 (9e20) vs. 9(9e10) ng/l), and the odds ratio (OR) for PH was increased in patients
with abnormal levels of uric acid (OR (95% CI) Z 3.1(1.1e8.8)). NT-proBNP and troponin-T
values above the 50th percentile, and uric acid and fibrin D-dimer values above the 90th
percentile were each associated with increased mortality.
Conclusions: A value of NT-proBNP below 95 ng/l may be used as a rule-out test for PH in ILD,
while an abnormal value of uric acid is a risk factor for PH. NT-proBNP, troponin-T, uric acid
and fibrin D-dimer have prognostic value in ILD patients, while exhaled levels of NO do not
seem to predict PH or mortality.
ª 2012 Elsevier Ltd. All rights reserved.16 76 92.
.U. Andersen).
2 Elsevier Ltd. All rights reserved.
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Pulmonary hypertension (PH) is an important complication
to interstitial lung disease (ILD). In a recent study, we
estimated that the overall prevalence in a tertiary referral
centre was 14%.1 In accordance with previous reports,2,3 PH
was associated with a worse prognosis and is therefore
important to diagnose.
Gold standard for diagnosis of PH is right heart cathe-
terisation (RHC). Echocardiography is a widely used
screening tool, but may not, however, be readily available
to pulmonologists. Therefore biomarkers as first line
screening tools are warranted. A number of biomarkers for
PH have been proposed, including NT-pro brain natriuretic
peptide (NT-proBNP) and troponin-T of which detectable
levels are related to higher mortality in pulmonary arterial
hypertension (PAH).4 Furthermore, elevated levels of fibrin
D-dimer and uric acid have been demonstrated in PAH,4
while lower levels of exhaled nitric oxide (NO) have been
associated with ILD and PH in scleroderma patients.5
The aim of this study was to investigate the diagnostic
value for PH and the prognostic significance of the above
mentioned biomarkers in ILD patients.
Methods
The present study is an analysis of a previously described
cohort of 212 patients enrolled in a cross-sectional study at
a tertiary referral centre for diagnosis and evaluation of
ILD.1
Briefly, the study was approved by The Danish Research
Ethics Committee, Region Central Jutland (Issue nr: M-
20080219) and conducted in accordance with the Helsinki
Declaration.
All patients with a diagnosis of ILD at the centre were
eligible, and participants had echocardiography performed
for the purpose of the study. PH was defined as a tricuspid
regurgitation pressure gradient (TR) >40 mmHg, right
ventricular dilatation or a tricuspid annular plane systolic
excursion <1.8 cm. Patients fulfilling one or more of these
criteria were asked to undergo right heart catheterization
(RHC). Patients were defined as having PH if they were
screened positive by echocardiography and fulfilled the
criteria for PH on RHC6 or if they were screened positive by
echocardiography, but did not undergo RHC. Patients
screened negative for PH by echocardiography, and patients
who were screened positive by echocardiography but had
a MPAP<25 mmHg at RHC were defined as non-PH patients.1
Biomarkers
Venous blood samples were analysed routinely for NT-
proBNP, troponin-T, uric acid (cobas 6000 E/C, Roche,
West Succex, England) and fibrin D-dimer (Sta, Stago,
Asnie`res sur Seine, France) at the hospital’s CME-
accredited laboratory. Upper limit of normal was 300 ng/l
for NT-proBNP, 0.5 mg/l for fibrin D-dimer and 0.40 mmol/l
for uric acid. During enrolment, the reagent for troponin-T
(Troponin T, fourth generation reagent,Roche, West Suc-
cex, England) with a detection level of 20 ng/l and an upper
limit of normal of 30 ng/l was replaced by a new reagentwith a higher sensitivity (TNT-HS, Roche, West Succex,
England). This analysis had a detection level of 9 ng/l and
an upper limit of normal of 50 ng/l.
Exhaled NO was measured by the aerocrine NIOX MINO
(Intramedic, Copenhagen, Denmark).
Data analysis
Data were analysed in Stata/IC 10 (StataCorp, College
Station, Texas, USA). Normality was checked by histograms.
Parametric data were analysed using Student’s t-test, non-
parametric data by rank sum test.
The discriminatory power for PH for each biomarker was
analysed by receiver operating characteristic (ROC) curves.
Cut-off values for exclusion or identification of PH were
evaluated, and sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were
calculated if the area under the ROC curve (AUC) was
higher than 0.8.
Survival was analysed with time since inclusion as time
scale. Follow-up was censored eight months after inclusion
of the last patient. Mortality was estimated by Kaplan-
Meier curves, and differences in hazard ratio for death (HR)
between patients with biomarker values cut at the 50th and
90th percentile of the values in the present study, was
analysed by Cox-proportion hazard model. Proportionality
was validated by logelog plots.
Parametric data are expressed as mean  standard error
of the mean (SEM), non-parametric as medians with inter
quartile ranges, HR and AUCs are expressed with standard
errors (SE). Odds ratios (OR), sensitivity, specificity, PPV
and NPV are expressed with 95% CIs. Analyses of troponin-T
were made on all patients (n Z 208) and separately in
patients examined after introduction of the high-sensitivity
method (nZ 164). Results based on the analysis of patients
after the introduction of the new method are shown.
A p-value below 0.05 was regarded as statistically
significant.
Results
Patients
Characteristics of the 212 participants in the study are
described in details elsewhere.1 Briefly, 23% had idiopathic
pulmonary fibrosis (IPF), 15% had non-specific interstitial
pneumonitis, 6% had desquamative interstitial pneumo-
nitis, 7% had hypersensitivity pneumonitis, 19% had ILD
associated with a rheumatological disorder, 10% had
sarcoidosis stage IIeIV and 20% had other types of ILD.1 The
mean total lung capacity, diffusion capacity, forced expi-
ratory volume in one second and forced vital capacity were
69  1, 45  1, 67  1 and 71  2% of expected, respec-
tively. Mean 6-min walk test was 424  8 m. A total of 16%
of patients had a history of cardiac disease defined as heart
failure, ischemic heart disease, previous myocardial
infarction, or atrial fibrillation.
Time of inclusion was defined as the date for analysis of
plasma biomarkers. One hundred and ninety-five patients
had echocardiography performed at inclusion. Seventeen
were examined prior to inclusion (median 1.5 (1e2.5)
Table 1 Distribution of diagnoses in patients without and
with PH
ILD diagnosis
(% of patients)
No PH,
n Z 179
PH,
n Z 29
P PH vs
no PH
IPF 21 41 0.01*
NSIP 16 3 0.07
DIP 7 3 0.5
Hypersens. pneumonitis 8 0 0.1
Rheumatologic disease 19 21 0.8
Sarcoidosis 9 10 0.9
Endstage 3 10 0.05*
Other 17 10 0.3
n indicates number of patients in each group. Data were
available in all patients. *p < 0.05 vs no PH analysed by
proportion test. Results are expressed as proportions. Other
comprises: (eosinophilic pneumonia, Respiratory bronchiolitis
associated-ILD, cryptogenic organizing pneumonia,, lymphoid
interstitial pneumonia, alveolar proteinosis, Histiocytosis X,
medically induced ILD, inorganic dust exposure, acute inter-
stitial pneumonitis, granulomatous interstitial lung disease,
unclassified). Hypersens. Pneumonitis: hypersensititivity pneu-
montitis. *Proportion significantly higher than in patients with
no PH.
Biomarkers for pulmonary hypertension in ILD 1751months). Thirty patients were screened positive for PH by
echocardiography. Nine patients with PH had dilatation of
the right ventricle. In four, PH status was undeterminable.
RHC was performed in 18 of these and in only one patient,
the diagnosis was discarded. Hence, 29 were defined as
having PH. All diagnostic groups except for hypersensitivity
pneumonitis were represented in the PH-group, and
compared to non-PH patients a larger fraction of patients
with PH had IPF and endstage ILD (Table 1). Patients in
whom PH was confirmed by RHC had significantly higher
tricuspid pressure gradients, and significantly lower Dlco
and 6-min walk test distance compared to patients in whom
the PH diagnosis was based only on echocardiography
(Table 2).NT-proBNP
There was a significant relationship between higher values
of NT-proBNP and the presence of PH (area under ROCTable 2 Patients with pulmonary hypertension established by r
Dlco (% of expected) RHC confirmed PH
24  3
TLC (% of expected) 65  4
FVC (% of expected) 59  6
FEV1 (% of expected) 54  6
6 MWT distance (m) 275  25
TR (mmHg) 65  4.3
TAPSE (cm) 1.8  0.13
Comparison of patients with PH verified by right heart catheterisation
RHC, right heart catherisation; ehco, echocardiography; Dlco, diffusi
FEV1, forced expiratory volume in 1 s; 6MWT, 6-min walk test; TR,
systolic excursion. n indicates number of patients from whom data wcurve (AUC) Z 0.86)) (Fig. 1A). With a cut-off value of
95 ng/l, the sensitivity, specificity, PPV and NPV was 96
(82e100), 52 (44e60), 25 (17e33) and 99 (94e100)%,
respectively. Forty-five percent of patients had NT-proBNP
values below 95 ng/l (Fig. 1B).
NT-proBNP values above the 50th percentile and 90th
percentile were associated with a higher mortality
compared to patients with values less than 106 ng/l,
respectively) (Fig. 1C & Table 3).Troponin-T
AUC for troponin-T to detect PH was 0.62 ± 0.007
Levels of troponin-T were higher in PH patients when
compared to non-PH patients (Fig. 2A). Furthermore, PH
patients with dilatation of the right ventricle had higher
Troponin-T levels than PH patients without right ventricular
dilatation (Median: 25 (16e84) vs 9 (9e15) ng/l, pZ 0.02).
Troponin-T values above the 90th percentile were asso-
ciated with a higher mortality (Fig. 3A & Table 3). Only with
regard to mortality, differences between the results based
on the analysis of the whole population and the sub pop-
ulation of patients with the high-sensitivity Troponin-T-
analysis were present (see Table 3).Uric acid
AUC for detection of PH was 0.53  0.07. There were no
significant differences between uric acid values in patients
with and without PH (Fig. 2B). However, values above the
normal reference level (0.4 mmol/l), raised the odds for PH
(OR Z 3.1 (95 % CI: 1.1e8.8)).
Values above the 50th and 90th percentile were associ-
ated with a higher mortality (Fig. 3B &Table 3).Fibrin D-dimer
AUC for the detection of PH was 0.44  0.07. There were no
differences in values between PH and non-PH patients
(Fig. 2C). A total of 34% of measured fibrin D-dimer values
were above reference value (0.5 mg/l). OR for PH in those
with abnormally elevated values were not increased
(OR Z 1.4 (0.6e3.2) p Z 0.4).ight heart catheterisation or echocardiography.
n PH based on echo n p (PH vs No PH)
17 37  6 11 0.03*
17 65  4 12 0.9
17 61  6 12 0.9
16 57  6 12 0.8
16 358  29 12 0.04*
16 53  4 12 0.06
14 2.01  0.14 12 0.2
and patients with a diagnosis of PH based on echocardiography.
on capacity; TLC, total lung capacity; FVC, forced vital capacity;
tricuspid regurgitation gradient; TAPSE, tricuspid annular plane
ere available. Results are means  SEM.
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Figure 1 (A) ROC curve for NT-proBNP to detect PH
(n Z 205). (B) Scatter plots of NT-proBNP in patients without
(n Z 177) and with PH (n Z 28). Dotted line shows cut-off
value at 95 ng/l. Error bars shows median with inter quartile
ranges. (C) survival curves for patients with NT-proBNP values
within the 0e50 (n Z 106), 50e90th (n Z 83) and 90e100th
percentile (nZ 20)(A þ B): *p < 0.05 vs no PH. (C): *p < 0.05 vs
0e50th percentile yp < 0.05 vs 50e90th percentile.
1752 C.U. Andersen et al.However,mortalitywas increased in patientswithfibrinD-
dimer levels in theupper90thpercentile (Fig. 3CandTable3).
Exhaled NO
AUC for the detection of PH was 0.44  0.07. A total of 14%
of patients could not cooperate to exhaled NO-measurements, primarily due to breathlessness. Patients
from whom values were not obtained had significantly
lower lung function parameters (data not shown).
There were no relations between values of exhaled NO
and PH (Fig. 2D) or mortality (Fig. 3D, Table 3).
Discussion
The main findings of this study were that a value of NT-
proBNP below 95 ng/l effectively ruled out PH in ILD
patients. Abnormally high uric acid levels was a risk factor
for PH. High values of NT-proBNP, troponin-T, uric acid and
fibrin d-dimer were associated with a worse prognosis.
Exhaled NO had no relation to the presence of PH or
mortality.
NT-proBNP
To our best knowledge, the present study shows for the first
time that NT-proBNP may be used as a rule-out test for PH
in ILD patients. Studies with a limited number of ILD
patients have shown that BNP were able to detect severe
PH in ILD,7,8 while another study, primarily including COPD
patients, concluded that NT-proBNP was not able to detect
mild PH, because NT-proBNP levels were generally beneath
the reference value.9 In accordance with that, we found
that a very low cut-off value of NT-proBNP should be used if
NT-proBNP should be applied as a rule-out test. By using
a cut-off value of 95 ng/l, the presence of PH could be
excluded in 45% of patients, with a low risk of missing cases
of PH. NT-proBNP may therefore be used as a first-line
screening tool.
The results from the present study are supported by our
recent COPD study10 and findings in a study predominated
by asthma and COPD patients, where NT-proBNP values
below 93 pg/ml in men had a high NPV for the exclusion of
heart diseases,11 and also corresponds well with results
from Bonderman et al.12 who showed that a value of NT-
proBNP below 80 pg/ml in combination with parameters
on the electrocardiogram could be used to preclude pre-
capillary PH in various types of patients with suspected PH.
The finding that higher levels of NT-proBNP are associ-
ated with a poor prognosis in ILD patients also concurs with
previous findings of BNP as a prognostic marker in ILD
patients.13
Troponin-T, uric acid, fibrin D-dimer and exhaled
NO
Troponin-T may reflect myocardial injury caused by right
ventricular failure and was found to be related to a worse
prognosis in patients with precapillary PH.14,15 In accor-
dance, in the present study, an association between higher
levels of troponin-T and increased mortality was observed
in ILD patients. Furthermore, patients with PH had higher
troponin-T levels than non-PH patients, a difference that
may be ascribed to right ventricular dilatation.
In a study in patients with idiopathic pulmonary arterial
hypertension (iPAH), a notably larger proportion of iPAH
patients had abnormal uric acid values16 than observed in
the present study. This incongruence is probably explained
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Biomarkers for pulmonary hypertension in ILD 1753by higher MPAPs and more severe affection of the nucleic
acid metabolisation in iPAH patients. However, it appears
from the present study that abnormal levels of uric acid in
ILD patients are associated with both the presence of PH
and a higher mortality.
In iPAH, fibrin D-dimer is elevated.17 Few data exist on
fibrin D-dimer levels in ILD patients. In a study in IPF
patients,18 levels of fibrin D-dimer were 1.9e2.1 mg/ml
(reference value 0.5 mg/ml as in the present study). In
accordance, we found that a high percentage of ILD
patients had elevated levels. The absence of a relation-
ship to PH in the present study may be explained by the
role of fibrin D-dimer as an inflammatory marker. Inflam-
mation and fibrin deposition in the airways in ILD patients
may override the increase related to pulmonary vascular
fibrin turnover. The relation to a poorer prognosis may,
accordingly, be related to a more pronounced paren-
chymal affliction rather than to pulmonary vascular
disease.
To our knowledge this is the first study addressing the
use of exhaled NO as a diagnostic tool for PH and a prog-
nostic marker in ILD. Inflammation in the lungs that
increases NO production,19 may mask decreased
endothelial-derived NO in PH, and may explain whyNo
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Figure 3 (A) Survival curves for patients with troponin-T values within the 0e50 (n Z 114), 50e90 (n Z 34) and 90e100th
percentile (nZ 16). (B) Survival curves for patients with uric acid values within the 0e50 (nZ 113), 50e90 (nZ 74) and 90e100th
percentile (n Z 20). (C) Survival curves for patients with fibrin D-dimer values within the 0e50 (n Z 56), 50e90 (n Z 130) and
90e100th percentile (n Z 20). (D) Survival curves for patients with exhaled NO values within the 0e50 (n Z 86), 50e90 (n Z 63)
and 90e100th percentile (n Z 16). *p < 0.05 vs 0e50th percentile. yp < 0.05 vs 50e90th percentile.
1754 C.U. Andersen et al.exhaled NO was not a marker of PH. Recording of exhaled
NO was difficult to obtain in patients with more severe lung
function impairment, and we cannot exclude this may also
have contributed to the lack of predictability of exhaled NO
for PH in ILD patients.
Study limitations
It is a limitation that not all patients in the present study
were evaluated for PH by RHC. In a previous study, the
sensitivity for PH of an echo-estimated systolic pulmonaryblood pressure above 45 mmHg was high (85 %) in patients
with lung diseases.20 In the present study, we used an
overall evaluation of both the tricuspid pressure gradient
and right ventricular abnormalities. We rely on these
criteria in our clinical practice to exclude the presence of
PH, but the risk of false negative echocardiograms for PH,
and a following overestimation of the NPV of NT-proBNP
cannot be eliminated. The differences between PH-
patients with and without RHC, indicates that those 12
patients in whom RHC was not performed had milder PH,
but it cannot be excluded that a subset of them may not
Biomarkers for pulmonary hypertension in ILD 1755fulfil the diagnostic criteria. These potential false positives
would, though, not reduce the NPV of NT-proBNP.
The relatively small number of PH patients and the wide
spectrum of ILD diagnoses may also be a limitation; the
diagnostic value of the biomarkers could be confounded by
the distribution of ILD in PH- and non-PH patients, rather
than the presence of PH per se. However, this does not
appear to be the case as nearly all diagnostic categories
appeared in the PH-group, although IPF was over-
represented. The main source of circulating NT-proBNP
has been shown to be the heart.21 Thus, the NT-proBNP
results may not be largely affected by the specific ILD
type, while this concern may be greater for lung-derived
biomarkers such as exhaled NO. Conversely, the heteroge-
neity of the population in the present study may also be an
advantage, because it reflects reality at centres for eval-
uation of ILD. Consequently, this design may improve
applicability in practice.
Finally, the use of routine blood sample analyses with
the resulting intra assay variation can also be regarded as
a limitation. However, since routine tests are used in
practice, results obtained by this approach may also be
more readily applicable in the clinic.
Conclusions
A value of NT-proBNP below 95 ng/l may be used as a rule-
out test for PH in ILD, and abnormally high levels of uric
acid should increase the suspicion of PH in ILD patients.
Furthermore, NT-proBNP, troponin-T, uric acid and fibrin D-
dimer have prognostic value in ILD patients, while exhaled
levels of NO does not predict PH or mortality.
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